Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Oncology|September 7, 2016
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid TumorsEmiliano Calvo, Fadi Braiteh, Daniel Von Hoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2025
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2BDiwakar Davar, Zeynep Eroglu, Mohammed Milhem, et al.
Cancer Chemotherapy and Pharmacology|September 30, 2016
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumorsJohn Sarantopoulos, Sanjay Goel, Vincent Chung, et al.
Cancer Research|September 17, 2005
Selective identification of secreted and transmembrane breast cancer markers using Escherichia coli ampicillin secretion trapDeborah A Ferguson, Matthew R Muenster, Qun Zang, et al.
Investigational New Drugs|August 29, 2009
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative studyDonald A Richards, Paul R Kuefler, Carlos Becerra, et al.
The Oncologist|January 23, 2025
Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreductionVincent Chung, Angela Alistar, Carlos Becerra, et al.
Breast Cancer Research and Treatment|August 2, 2019
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancerVandana G Abramson, Mafalda Oliveira, Andrés Cervantes, et al.
Biomed Research International|October 2, 2015
Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular LymphomaDaniel Tusé, Nora Ku, Maurizio Bendandi, et al.
Cancer Chemotherapy and Pharmacology|February 17, 2020
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumorsAnthony W Tolcher, Razelle Kurzrock, Vincente Valero, et al.
Cancer Chemotherapy and Pharmacology|June 9, 2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancerJordi Rodon, Alejandro Pérez-Fidalgo, Ian E Krop, et al.
Pageof 4